We suggest you to use Amgen Inc fundamental analysis to see if markets are presently mispricing the company. In plain English you can use it to find out if Amgen Inc is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-eight available fundamental indicators for Amgen Inc which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Amgen Inc fundamentals including its EBITDA, Cash Flow from Operations and the relationship between Price to Book and Total Debt . Given that Amgen Inc has Price to Earning of 68.23 times, we suggest you validate Amgen Inc prevailing market performance to make sure the company can sustain itself down the road.Use Amgen to protect against small markets fluctuations. The stock experiences normal downward trend and little activity. Check odds of Amgen to be traded at $181.71 in 30 days
Amgen Inc Valuation Over Time
Amgen Company SummaryAmgen competes with Vertex Pharmaceuticals, Endo International, Abbott Laboratories, Allergan plc, and BIO RAD. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.
Amgen Shares Owned by Insiders vs Profit Margin
Amgen Inc is rated below average in shares owned by insiders category among related companies. It is number one stock in profit margin category among related companies fabricating about 57.73 of Profit Margin per Shares Owned by Insiders.